Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011;66(7):1267-74.
doi: 10.1590/s1807-59322011000700024.

Pharmacokinetics of cephalosporins in the neonate: a review

Affiliations
Review

Pharmacokinetics of cephalosporins in the neonate: a review

Gian Maria Pacifici. Clinics (Sao Paulo). 2011.

Abstract

The aim of this work was to review the published data on the pharmacokinetics of cephalosporins in neonates to provide a critical analysis of the literature as a useful tool for physicians. The bibliographic search was performed for articles published up to December 3, 2010, using PubMed. In addition, the book Neofax: A Manual of Drugs Used in Neonatal Care by Young and Mangum was consulted. The cephalosporins are mainly eliminated by the kidneys, and their elimination rates are reduced at birth. As a consequence, clearance is reduced and t1/2 is more prolonged in the neonate than in more mature infants. The neonate's substantial body water content creates a large volume of distribution (Vd) of cephalosporins, as these drugs are fairly water soluble. Postnatal development is an important factor in the maturation of the neonate, and as postnatal age proceeds, the clearance of cephalosporins increases. The maturation of the kidney governs the pharmacokinetics of cephalosporins in the infant. Clearance and t1/2 are influenced by development, and this must be taken into consideration when planning a cephalosporin dosage regimen for the neonate.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Neu HC. In vitro activity of ceftazidime, a β-lactamase stable cephalosporin. J Antimicrob Chemother. 1981;8((Suppl B)):131–4. - PubMed
    1. Williams JD. Classification of cephalosporins. Drugs. 1987;34((Suppl.2)):15–22. 10.2165/00003495-198700342-00004 - DOI - PubMed
    1. Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am. 1995;79:705–19. - PubMed
    1. Petri WA., JrPenicillins, cephalosporins, and other β-lactam antibiotics “The pharmacological basis of therapeutics” Brunton LL, Lazo JS, Parker KL, editors. 11th edition, 2006. pp 1127–1154.New York USA
    1. Martin E, Fanconi S, Kälin P, Zwingelstein C, Crevoisier C, Ruch W, et al. Ceftriaxone—bilirubin-albumin interactions in the neonate: an in vivo study. Eur J Pediatr. 1993;152:530–4. 10.1007/BF01955067 - DOI - PubMed

Publication types